What’s News in Earnings: Who Is Winning the Obesity-Drug Arms Race?
Bonus Episode for Nov. 4. The weight-loss-drug arms race is only heating up, as Novo Nordisk attempts to snatch drugmaker Metsera away from Pfizer. But can either company compete with Zepbound seller Eli Lilly? WSJ reporter Peter Loftus discusses what earnings from Big Pharma, including AbbVie, Bristol Myers Squibb…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from WSJ What’s News
See all episodes →Similar episodes from other shows
More like WSJ What’s News →
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?
Different Reads On The Consumer… And Pharma’s Obesity Drug Price Negotiations 11/5/25
Big deals in Big Pharma
Pfizer plays hardball in weight-loss drug fight
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.